[144] Health Catalyst, Inc SEC Filing

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) Form 144 summary: This notice reports a proposed sale of 3,138 restricted common shares through Morgan Stanley Smith Barney on 09/02/2025, with an aggregate market value of $10,552.15. The filer acquired these shares as restricted stock on 09/02/2025 as compensation. The filing also discloses two restricted stock sales by the same person in the past three months: 3,255 shares sold on 06/02/2025 for $11,831.27 and 6,057 shares sold on 06/05/2025 for $23,890.63. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Insider plans to sell a small block of restricted shares; proceeds and amounts are minor relative to total outstanding shares.

The proposed sale of 3,138 restricted shares valued at $10,552.15 is a routine disclosure under Rule 144. The filer acquired the shares as compensation on the same date listed for the proposed sale. Prior sales in June 2025 total 9,312 restricted shares for combined gross proceeds of $35,721.90. Given the issuer's reported outstanding shares of 70,373,625, these transactions represent an immaterial percentage of the float. This filing documents compliance with Rule 144 resale notice requirements rather than signalling a material company event.

Corporate Governance Expert

TL;DR: Filing is a standard Form 144 disclosure showing compliance; no new governance actions or disclosures are reported.

The form includes the required attestation that the seller is unaware of undisclosed material adverse information and identifies Morgan Stanley Smith Barney as the broker. The acquisition basis is stated as restricted stock granted as compensation. There are no departures from standard disclosure practice, no indication of a trading plan date, and no mention of accelerated insider activity beyond the listed sales. The filing serves transparency and regulatory compliance purposes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	3138	10552.15	70373625	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Restricted Stock	Health Catalyst, Inc.			3138	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Benjamin Landry c/o 10897 South River From Parkway #300 South Jordan UT 84095	Restricted Stock	06/02/2025	3255	11831.27
Benjamin Landry c/o 10897 South River From Parkway #300 South Jordan UT 84095	Restricted Stock	06/05/2025	6057	23890.63

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for HCAT report?

The filing reports a proposed sale of 3,138 restricted common shares to be sold on 09/02/2025 through Morgan Stanley Smith Barney with aggregate market value $10,552.15.

Who acquired the securities and how were they acquired?

The securities were acquired as restricted stock from Health Catalyst, Inc. on 09/02/2025 as compensation.

Were there any other recent sales by this person?

Yes. The filer sold 3,255 restricted shares on 06/02/2025 for $11,831.27 and 6,057 restricted shares on 06/05/2025 for $23,890.63.

Which broker is handling the proposed sale for HCAT?

The broker named in the filing is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 38th Floor, New York, NY.

How large is the proposed sale relative to HCAT's outstanding shares?

The proposed 3,138 shares compare to 70,373,625 shares outstanding as stated in the filing, representing an immaterial fraction of outstanding shares.